CCNA2 is a prognostic biomarker for ER+ breast cancer and tamoxifen resistance.
CCNA2 is a prognostic biomarker for ER+ breast cancer and tamoxifen resistance.
复制标题
DOI：
10.1371/journal.pone.0091771
复制
发表时间：
2014
期刊：
影响因子：
3.7
通讯作者：
Ji J
中科院分区：
文献类型：
--
作者：
Gao T;Han Y;Yu L;Ao S;Li Z;Ji J
识别有效的预后生物标志物和靶点对于雌激素受体阳性（ER+）乳腺癌的管理至关重要。CCNA 2（也称为CyclinA 2）属于高度保守的细胞周期蛋白家族，在各种癌症类型中显著过表达。在这项研究中，我们证明了CCNA 2在ER+乳腺癌患者的无远处转移生存期、无疾病生存期、无复发生存期和总生存期中具有显著的预测能力。我们还发现CCNA 2与他莫昔芬耐药密切相关。此外，基因集富集分析（GSEA）显示，其表达与内分泌治疗耐药样本中过表达的基因呈正相关。最后，通过CCNA 2-药物相互作用网络，我们展示了CCNA 2与几种现有的癌症药物之间的相互作用。总之，我们认为CCNA 2是ER+乳腺癌预后和监测他莫昔芬疗效的生物标志物。这也是一个很有前途的目标，为发展新的战略，以防止甚至扭转他莫昔芬耐药性。此外，CCNA 2表达可能有助于监测他莫昔芬的疗效和指导个性化治疗。然而，在将其应用于临床之前，还需要进行体内外实验和多中心随机对照临床试验。
Identification of effective prognostic biomarkers and targets are of crucial importance to the management of estrogen receptor positive (ER+) breast cancer. CCNA2 (also known as CyclinA2) belongs to the highly conserved cyclin family and is significantly overexpressed in various cancer types. In this study, we demonstrated that CCNA2 had significant predictive power in distant metastasis free survival, disease free survival, recurrence free survival and overall survival of ER+ breast cancer patients. We also found that CCNA2 was closely associated with tamoxifen resistance. In addition, gene set enrichment analysis (GSEA) revealed that its expression was positively associated with genes overexpressed in endocrine therapy resistant samples. Finally, though CCNA2-Drug interaction network, we demonstrated the interactions between CCNA2 and several available cancer drugs. Overall, we suggest that CCNA2 is a biomarker for the prognosis of ER+ breast cancer and monitoring of tamoxifen efficacy. It's also a promising target for developing new strategies to prevent or even reverse tamoxifen resistance. Moreover, CCNA2 expression may help monitoring tamoxifen efficacy and directing personalized therapies. Nevertheless, in vivo and in vitro experiments and multi-center randomized controlled clinical trials are still needed before its application in clinical settings.
登录
查看更多内容
影响因子：
16.6
作者：
Johansson, Henrik J.;Sanchez, Betzabe C.;Mundt, Filip;Forshed, Jenny;Kovacs, Aniko;Panizza, Elena;Hultin-Rosenberg, Lina;Lundgren, Bo;Martens, Ulf;Mathe, Gyongyver;Yakhini, Zohar;Helou, Khalil;Krawiec, Kamilla;Kanter, Lena;Hjerpe, Anders;Stal, Olle;Linderholm, Barbro K.;Lehtio, Janne
通讯作者：
Lehtio, Janne
影响因子：
3.8
作者：
Hiscox S;Baruha B;Smith C;Bellerby R;Goddard L;Jordan N;Poghosyan Z;Nicholson RI;Barrett-Lee P;Gee J
通讯作者：
Gee J
影响因子：
45.3
作者：
Goldhirsch, A;Glick, JH;Senn, HJ
通讯作者：
Senn, HJ
影响因子：
3.7
作者：
Davis AP;Wiegers TC;Johnson RJ;Lay JM;Lennon-Hopkins K;Saraceni-Richards C;Sciaky D;Murphy CG;Mattingly CJ
通讯作者：
Mattingly CJ
DOI：
10.1083/jcb.201102085
发表时间：
2012-01-09
期刊：
The Journal of cell biology
影响因子：
--
作者：
Arsic N;Bendris N;Peter M;Begon-Pescia C;Rebouissou C;Gadéa G;Bouquier N;Bibeau F;Lemmers B;Blanchard JM
通讯作者：
Blanchard JM